Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Chronic traumatic encephalopathy (2)
- MRI (2)
- Neurodegenerative disease (2)
- Traumatic brain injury (2)
- ARIA (1)
-
- Aducanumab (1)
- Aduhelm (1)
- Alzheimer’s disease (1)
- Amyloid imaging (1)
- Appropriate use (1)
- Biomarkers (1)
- Cognition (1)
- Cognitive function (1)
- College football (1)
- Composite index (1)
- Concussion (1)
- Dementia-related psychosis (1)
- Football (1)
- Head trauma (1)
- MRS (1)
- National Football League (1)
- Neuroimaging (1)
- Patient trial (1)
- Pimavanserin (1)
- Positron emission tomography (1)
- Remote assessment (1)
- Repetitive head impacts (1)
- Subconcussion (1)
- Tau (1)
- Titration (1)
Articles 1 - 4 of 4
Full-Text Articles in Medicine and Health Sciences
Developing Methods To Detect And Diagnose Chronic Traumatic Encephalopathy During Life: Rationale, Design, And Methodology For The Diagnose Cte Research Project, Jeffrey Cummings, Numerous Authors, See Full List Below
Developing Methods To Detect And Diagnose Chronic Traumatic Encephalopathy During Life: Rationale, Design, And Methodology For The Diagnose Cte Research Project, Jeffrey Cummings, Numerous Authors, See Full List Below
School of Medicine Faculty Publications
Background: Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease that has been neuropathologically diagnosed in brain donors exposed to repetitive head impacts, including boxers and American football, soccer, ice hockey, and rugby players. CTE cannot yet be diagnosed during life. In December 2015, the National Institute of Neurological Disorders and Stroke awarded a seven-year grant (U01NS093334) to fund the “Diagnostics, Imaging, and Genetics Network for the Objective Study and Evaluation of Chronic Traumatic Encephalopathy (DIAGNOSE CTE) Research Project.” The objectives of this multicenter project are to: develop in vivo fluid and neuroimaging biomarkers for CTE; characterize its clinical presentation; refine …
Trial Of Pimavanserin In Dementia-Related Psychosis, Pierre N. Tariot, Jeffrey L. Cummings, Maria E. Soto-Martin, Clive Ballard, Deniz E. Erten-Lyons, David L. Sultzer, Davangere P. Devanand, Daniel Weintraub, Bradley Mcevoy, James M. Youakim, Srdjan Stankovic, Erin P. Foff
Trial Of Pimavanserin In Dementia-Related Psychosis, Pierre N. Tariot, Jeffrey L. Cummings, Maria E. Soto-Martin, Clive Ballard, Deniz E. Erten-Lyons, David L. Sultzer, Davangere P. Devanand, Daniel Weintraub, Bradley Mcevoy, James M. Youakim, Srdjan Stankovic, Erin P. Foff
School of Medicine Faculty Publications
BACKGROUND Patients with dementia due to neurodegenerative disease can have dementia-related psychosis. The effects of the oral 5-HT2A inverse agonist and antagonist pimavanserin on psychosis related to various causes of dementia are not clear. METHODS We conducted a phase 3, double-blind, randomized, placebo-controlled discontinuation trial involving patients with psychosis related to Alzheimer's disease, Parkinson's disease dementia, dementia with Lewy bodies, frontotemporal dementia, or vascular dementia. Patients received open-label pimavanserin for 12 weeks. Those who had a reduction from baseline of at least 30% in the score on the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions (SAPS-H+D, with higher …
Aducanumab: Appropriate Use Recommendations, Jeffrey Cummings, P. Aisen, L. G. Apostolova, A. Atri, S. Salloway, M. Weiner
Aducanumab: Appropriate Use Recommendations, Jeffrey Cummings, P. Aisen, L. G. Apostolova, A. Atri, S. Salloway, M. Weiner
School of Medicine Faculty Publications
Aducanumab has been approved by the US Food and Drug Administration for treatment of Alzheimer’s disease (AD). Clinicians require guidance on the appropriate use of this new therapy. An Expert Panel was assembled to construct Appropriate Use Recommendations based on the participant populations, conduct of the pivotal trials of aducanumab, updated Prescribing Information, and expert consensus. Aducanumab is an amyloid-targeting monoclonal antibody delivered by monthly intravenous infusions. The pivotal trials included patients with early AD (mild cognitive impairment due to AD and mild AD dementia) who had confirmed brain amyloid using amyloid positron tomography. The Expert Panel recommends that use …
Assessing Clinical Change In Individuals Exposed To Repetitive Head Impacts: The Repetitive Head Impact Composite Index, Charles Bernick, Guogen Shan, Lauren Bennett, Jay Alberts, Jeffrey Cummings
Assessing Clinical Change In Individuals Exposed To Repetitive Head Impacts: The Repetitive Head Impact Composite Index, Charles Bernick, Guogen Shan, Lauren Bennett, Jay Alberts, Jeffrey Cummings
Public Health Faculty Publications
Background: There is a current lack of any composite measure for the effective tracking and monitoring of clinical change in individuals exposed to repetitive head impacts (RHI). The aim of this study is to create a composite instrument for the purposes of detecting change over time in cognitive and behavioral function in individuals exposed to RHI. Methods: The data to derive the composite instrument came from the Professional Fighters Brain Health Study (PFBHS), a longitudinal study of active and retired professional fighters [boxers and mixed martial arts (MMA) fighters] and healthy controls. Participants in the PFBHS underwent assessment on an …